Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction

Non-small Cell Lung Cancer Clinical Trial

Official title:

Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment, Outcome, and Prognosis Prediction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03053804
• Other study ID #: 201501073RINA
• Status: Recruiting
• Phase: N/A
• First received: October 30, 2016
• Last updated: February 14, 2017
• Start date: March 2015
• Est. completion date: December 2018

Study information

• Verified date: November 2016
• Source: National Taiwan University Hospital
• Contact: Yeun-Chung Chang
• Phone: 02-23123456*65566
• Email: ycc5566[@]ntu.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a study that hypothesize that MR/PET can have better information than current CT image study, about the medical or surgical treatment outcome of lung cancer

Description:

The investigators analyze tumor size、ADCmean、ADCmin、DCE、SUVmax、SUVmin、etc in MR/PET study，to compare its efficacy with other image studies in tumor malignancy grade, systemic involvement detection, treatment outcome after medical target therapy and treatment outcome after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Age: > 20 years old.

2. Patients have confirmed lung cancer by histopathological methods (fiber, bronchoscopy, lung biopsy, open chest biopsy, pleural effusion exfoliated cells, sputum exfoliated cells)

3. Patients voluntarily to join this study and signed informed consents.

Exclusion Criteria:

1. Any body metal implants (pacemaker implantation, nerve stimulator, vascular stent, aneurysm clip, eye foreign body, the inner metal prosthesis) or artificial heart valves

2. Patients with claustrophobia to MRI examination

3. Patients who are reluctant to comply with follow-up and subsequent examination

4. The other condition that do not meet the inclusion criteria.

5. Pregnancy.

6. Age < 20 years old.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Radiation:
• MR/PET
MR/PET with contrast media and FDG-18

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
National Taiwan University Hospital	National Taiwan University Hospital, Yun-Lin Branch

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline PET/MR parameters at 2 months after treatment		2 months after treatment